Category Archives: Psoriasis

Psoriasis remedies book teaches how to get rid of psoriasis naturally. Katy Wilson, medical researcher, has authored her new book Psoriasis Remedies to help readers get rid of psoriasis using at-home remedies that do not require creams or medical solutions.

Leesburg, VA (PRWEB) October 17, 2012

Millions of Americans and more worldwide suffer from skin conditions like psoriasis. Medical research has confirmed studies globally for the past two decades by leading medical doctors. While remedies are available medically, not all people that seek treatment receive results that are satisfactory for reducing the redness and itchiness that comes with psoriasis.

The Psoriasis Remedies book was written exclusively to help men, women and children that suffer daily from the symptoms of psoriasis. The research that is included in this book was used to cure the skin conditions of the author as well as many that participated in early testing of the findings. These natural methods for curing psoriasis are based on the authors research and have not been evaluated by medical professionals.

There are certain dietary changes that can be implemented for someone that has psoriasis according to a portion of the Psoriasis Remedies book. Avoiding certain food groups and ingesting other food groups is one way to combat the symptoms and appearance of psoriasis on the skin.

The Psoriasis Remedies book is now available for download as a PDF. This book can be read on any digital reader, personal computer, mobile phone or laptop. A complete 60-day refund is offered to any person that does not cure or drastically notice relief in appearance of symptoms of psoriasis according to the author.

About Psoriasis Remedies

Katy Wilson authored the Psoriasis Remedies e-book after unsuccessfully using medical treatments to cure her psoriasis. This medical researcher put her expert skills to work and has developed multiple remedies to lessen redness, itching and skin appearance for psoriasis sufferers. While these methods have cured the authors and other peoples conditions, the Psoriasis Remedies book is based on medical research and has not been evaluated by medical professionals. This book is written as an alternative to medicinal treatments.

Jody Taylor Psoriasis Remedies 206-424-0321 Email Information

Go here to see the original:
Psoriasis Remedies Book Teaches How to Get Rid of Psoriasis

Islamabad, Oct 16 (IANS) More than five percent of Pakistanis suffer from a life-long skin disorder called psoriasis and this percentage is increasing each passing year, health experts have said.

The government was, however, neglecting the health sector, and there has been no budgetary allocation for non-communicable diseases in the 2012-13 budget, the Daily Times reported.

Psoriasis is a life-long skin disorder that causes red, scaly patches or lesions on the skin. The lesions can show up on any area of the skin. Psoriasis affects nearly three percent of the world's population.

At a conference titled "Dermato-Expert League 2012", Brig. Zafar Iqbal Sheikh, head of dermatology at the Military Hospital is Rawalpindi, said there was lack of awareness among people about psoriasis.

"The patient suffering from the disease is ignorant of the fact that he would have to continue his treatment for life. This disease is non-communicable but due to lack of knowledge, people avoid being social with psoriasis patients," Sheikh said.

The World Psoriasis Day is observed every year Oct 29.

Here is the original post:
Rise in number of Pakistanis suffering from psoriasis

Washington, October 16 (ANI): Researchers have found a strong correlation between psoriasis and diabetes following an analysis of 27 studies, which link the scaly skin rash and the blood sugar disorder.

UC Davis researchers led the review.

"Our investigation found a clear association between psoriasis and diabetes," said April Armstrong, assistant professor of dermatology at UC Davis and principal investigator of the study.

"Patients with psoriasis and their physicians need to be aware of the increased risk of developing diabetes so that patients can be screened regularly and benefit from early treatment," he noted.

Psoriasis is a common skin problem that tends to run in families. It causes a raised red, flaky and sometimes itchy rash, often on the elbows and knees, although it can appear anywhere. It is believed to be an autoimmune disease, in which the body regards its own skin as foreign and mounts an inflammatory response.

Armstrong and her colleagues combined data from 27 observational studies of patients with psoriasis, in what is known as a meta-analysis. Five of the studies assessed the incidence of diabetes- that is, how many patients with psoriasis developed diabetes during the course of a study, which ranged from 10 to 22 years.

The other studies assessed the prevalence of diabetes - how many patients already had diabetes at the outset of a study. Altogether, the studies evaluated more than 314,000 people with psoriasis and compared them to 3.7 million individuals (controls) without the disease.

Some of the studies classified patients by disease severity. The aggregate data for these studies showed that patients with mild psoriasis are over 1.5 times more likely to have diabetes than the general population while those with severe disease are nearly twice as likely. Among studies that assessed incidence, patients with psoriasis had a 27 percent increased risk of developing diabetes compared with the general population.

All but one study analysing incidence found a link between psoriasis and diabetes. These studies included patient data from outpatient clinics, insurance claims and hospitals. Diabetes rates were similar in patients despite ethnicity or country where the study was conducted.

"The large sample size and consistent association between psoriasis and diabetes make these study findings very strong and suggest an underlying physiological link between the two diseases," said Armstrong, who directs the Dermatology Clinical Research Unit at UC Davis and the teledermatology program.

View original post here:
Psoriasis nearly doubles diabetes risk

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases. Idera anticipates top-line data from this study will be available by year-end 2012. TLRs are a class of proteins that play a key role in both inflammation and immunity. Through the inhibition of specific TLRs, Ideras candidates may represent a novel approach for the treatment of psoriasis, lupus and other autoimmune diseases.

In this Phase 2 proof-of-concept study, we are evaluating multiple endpoints to assess the clinical activity of IMO-3100, including the impact on Psoriasis Area Severity Index (PASI), mean focal psoriasis severity, and Physician Global Assessment (PGA) scores, said Dr. Robert Arbeit, Vice President of Clinical Development at Idera. In addition to the clinical assessments, we are evaluating biopsies of psoriasis plaques for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action.

We have made significant progress in advancing our autoimmune disease program, including the completion of enrollment in the Phase 2 trial of IMO-3100 in patients with psoriasis. said Dr. Sudhir Agrawal, Chief Executive Officer of Idera. In addition, our investigational new drug (IND) application for IMO-8400, a lead candidate for lupus, is now active. We expect our phase 2 study of IMO-3100 and planned clinical trials of IMO-8400 will help us to establish the benefits of inhibiting Toll-like Receptor-mediated pathways, which include controlling the induction of multiple cytokines, such as TNF-, IL-12, IL-6, and IL-17, as well as downstream signaling. We look forward to reporting top-line data from the Phase 2 study of IMO-3100 in psoriasis and initiating clinical development of IMO-8400 before the end of 2012.

Idera also announced today that its Investigational New Drug application for IMO-8400 with the US Food and Drug Administration is now active. IMO-8400, an antagonist of TLRs 7, 8, and 9, is Ideras second lead candidate for use in treating autoimmune diseases, with lupus selected as an initial indication for clinical development. Idera anticipates initiating a Phase 1 dose escalation trial during the fourth quarter of 2012 to evaluate the safety and pharmacodynamics of IMO-8400 in healthy subjects. Following successful completion of the Phase 1 study, Idera expects to initiate a Phase 2 clinical trial of IMO-8400 in patients with lupus.

Recent and Upcoming Autoimmune Disease Program Milestones

Fourth Quarter 2012:

Year 2013:

About TLRs and Idera's Pipeline

Toll-like Receptors (TLRs) play a key role in inflammation and immunity. Of the 10 human TLRs identified to date, Idera is developing compounds targeted to TLRs 3, 7, 8, and 9, which are expressed in different cells and serve unique functions. Using its chemistry-based approach, Idera has created novel drug candidates that modulate immune responses through either activation or inhibition of specific TLRs. Inhibition of specific TLRs may be useful in treating autoimmune disorders, such as systemic lupus erythematosus (SLE), psoriasis, and rheumatoid arthritis, by blocking the induction of multiple cytokines and signaling pathways. Idera's lead clinical candidates for application in autoimmune diseases are IMO-3100, an antagonist of TLR7 and TLR9, and IMO-8400, an antagonist of TLRs 7, 8, and 9.

See the original post here:
Idera Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients with Psoriasis

ScienceDaily (Oct. 15, 2012) An analysis of 27 studies linking psoriasis in 314,000 individuals with diabetes has found strong correlation between the scaly skin rash and the blood sugar disorder that predisposes patients to heart disease, say UC Davis researchers who led the review.

The findings appear in the Archives of Dermatology.

"Our investigation found a clear association between psoriasis and diabetes," said April Armstrong, assistant professor of dermatology at UC Davis and principal investigator of the study. "Patients with psoriasis and their physicians need to be aware of the increased risk of developing diabetes so that patients can be screened regularly and benefit from early treatment."

Psoriasis is a common skin problem that tends to run in families. It causes a raised red, flaky and sometimes itchy rash, often on the elbows and knees, although it can appear anywhere. It is believed to be an autoimmune disease, in which the body regards its own skin as foreign and mounts an inflammatory response.

Armstrong and her colleagues combined data from 27 observational studies of patients with psoriasis, in what is known as a meta-analysis. Five of the studies assessed the incidence of diabetes -- that is, how many patients with psoriasis developed diabetes during the course of a study, which ranged from 10 to 22 years. The other studies assessed the prevalence of diabetes -- how many patients already had diabetes at the outset of a study. Altogether, the studies evaluated more than 314,000 people with psoriasis and compared them to 3.7 million individuals (controls) without the disease.

Some of the studies classified patients by disease severity. The aggregate data for these studies showed that patients with mild psoriasis are over 1.5 times more likely to have diabetes than the general population while those with severe disease are nearly twice as likely. Among studies that assessed incidence, patients with psoriasis had a 27 percent increased risk of developing diabetes compared with the general population.

All but one study analyzing incidence found a link between psoriasis and diabetes. These studies included patient data from outpatient clinics, insurance claims and hospitals. Diabetes rates were similar in patients despite ethnicity or country where the study was conducted.

"The large sample size and consistent association between psoriasis and diabetes make these study findings very strong and suggest an underlying physiological link between the two diseases," said Armstrong, who directs the Dermatology Clinical Research Unit at UC Davis and the teledermatology program.

While additional research is need to understand how the two diseases are associated, Armstrong believes altered immune pathways may make psoriasis patients more susceptible to developing diabetes.

"There is evidence that fat cells in psoriasis patients may not function normally," she said. "These cells secrete inflammatory substances known as cytokines that increase insulin resistance in the liver and muscle and initiate destruction of insulin-producing cells in the pancreas."

Excerpt from:
People with severe psoriasis nearly twice at risk for diabetes

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2r4sgn/psoriasis_thought) has announced the addition of the "Psoriasis Thought Leader Panel #22 2012-04" report to their offering.

Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development.

The Panel Weighs in On:

- The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals.

- Increases and decreases in cardiovascular events associated with inhibitors of TNF, IL23, IL17 and IL12.

- Advantages/disadvantages of IL23/IL12 vs p19 inhibitors.

- Advantages of a pure IL12 inhibitor

- Advantages/drawbacks for broad vs subreceptor selective IL17 approaches.

- Combinations and immunosuppression

More:
Research and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of Persepectives from 6 Key Opinion Leaders

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2rw494/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Psoriasis" to their offering.

Psoriasis is a chronic inflammatory skin disease that, despite being non-life-threatening, has a tremendous impact on patients' quality of life. While topical therapies remain the mainstay of psoriasis treatment, the heightened awareness of psoriasis as a systemic disorder has led to an increased use of both conventional and biological systemic agents.

New entrants to the topicals arenaGalderma's vitamin D3 ointment Vectical (calcitriol) and Warner Chilcott's fixed-dose combination Taclonex (calcipotriene/betamethasone dipropionate)have increased the competition for patient share among topical agents owing to their more convenient administration (Taclonex) or steroid-sparing capacity (Vectical). In the moderate-to-severe psoriasis segment, the suboptimal side-effect profiles of the commonly used conventional systemics (i.e., methotrexate, cyclosporine) have opened the playing field to several biologics.

Among these, Amgen/Pfizer/Stiefel's TNF-a inhibitor Enbrel (etanercept) has historically captured the nearly all of biologics-eligible patients owing to dermatologists' comfort with its longstanding efficacy and safety record. However, Enbrel's positioning in the psoriasis treatment algorithm is becoming more vulnerable in light of increasing competition from newer entrants such as Abbott's Humira (adalimumab) and Janssen Biotech's interleukin-12 and -23 (IL-12/23) inhibitor Stelara (ustekinumab), both of which offer efficacy superior to that of Enbrel.

While Humira is establishing itself as a first-line biologic, Stelara's novel mechanism of action and limited long-term safety data have handicapped its uptake. Using patient-level claims data, this report determines the share of each currently marketed drug or class of drugs by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

Key Topics Covered:

1. Background

2. Key Findings for Newly Diagnosed Patients

3. Key Findings for Recently Treated Patients

Read more from the original source:
Research and Markets: Key Findings from Treatment Algorithms: Psoriasis

PETAH TIKVA, Israel, Oct. 9, 2012 /PRNewswire/ --Can-Fite BioPharma (TASE: CFBI; OTC: CANFY) announced today the continuation of patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating steadily over the 24-week treatment period. These clinical effect data corroborate the published Phase 2 study and confirm the dose selection, while the favorable safety profile of CF101 further supports its development for the systemic treatment of moderate-to-severe psoriasis. To allow the trial to meet its full objectives, the company therefore intends to complete patient enrollment for this Psoriasis Phase 2/3 clinical study comparing CF101-2 mg BID to placebo, as standalone therapy. The study will include approximately 300 patients overall and is currently conducted in 17 U.S., European and Israeli medical centers.

Psoriasis is a skin condition that affects 2% to 3% of the general population. The psoriasis therapeutic market is estimated at $3.5 billion annually and is dominated by biological drugs.

Can-Fite CEO Pnina Fishman, Ph.D., commented, "We are pleased to continue the clinical development plan of CF101, a small molecule orally bioavailable drug, based on its encouraging therapeutic index. CF101's anti-inflammatory effect, its well-defined mechanism of action, and the excellent safety profile, all suggest this drug is an attractive candidate for the treatment of psoriasis."

The company also announced that it has listed and begun trading of its American Depository Receipts (ADRs). Shares of the ADRs launched on October 2nd, 2012 on the over-the-counter (OTC) market under the symbol CANFY. The Company's ordinary shares trade on the Tel Aviv Stock Exchange under the symbol CFBI and each ADR share represents 50 ordinary shares.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase 2 clinical studies. CF101 is currently developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3). CF101 is also developed for ophthalmic indications including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis by OphthaliX (OPLI), a subsidiary of Can-Fite.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (CFBI.TA). American Depository Receipts of the company are traded on the over-the-counter market (CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman's scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest (OPLI).

Contact:

KCSA Strategic Communications Jeff Corbin / Phil Carlson jcorbin@kcsa.com/ pcarlson@kcsa.com 212-896-1233

See the rest here:
Interim Analysis Supports Continuation of Can-Fite's Phase 2/3 Psoriasis Clinical Study with CF101

Psoriasis Free for Life by Katy Wilson now available as a holistic treatment for Psoriasis. More information can be found at http://bestguidesreviews.com/psoriasis-free-for-life/.

(PRWEB) October 08, 2012

The guide is an eBook created by Katy Wilson. She was a former psoriasis sufferer who turned out victorious against psoriasis after many years. This sad condition pushed her to explore various methods of curing psoriasis and her eBook can be termed as "a gift to all psoriasis sufferers". The main theme of the Psoriasis free for life guide is giving the body the needed ammo required to fight this auto-immune disease. The treatment detailed by the guide can also be done at home.

The Psoriasis Free for Life Guide explains the various causes of psoriasis and how it can be treated naturally. It dwells on all types of Psoriasis like:

It also includes bonus information as listed below:

Those who wish to treat psoriasis once and for all, and learn how to improve their overall health can take advantage of this eBook. The Psoriasis Free For life guide offers something special for psoriasis sufferers.

The Psoriasis Free for Life Guide is now available at http://bestguidesreviews.com/psoriasis-free-for-life/.

Admin BestGuidesReviews 917-72-00-66-8 Email Information

View original post here:
Psoriasis Free For Life Guide for Natural Psoriasis Treatment Now Available

By Paul G. Donohue, M.D. and Keith Roach, M.D.

October 06, 2012 12:00 AM

DEAR DRS. DONOHUE AND ROACH: Please give me new medicine information for psoriasis. I break out on my scalp very bad, and also on my face, back, chest and arms. It's slowly getting worse. Sometimes my skin is very itchy.

M.T.

Psoriasis is another illness you can blame the immune system for. It sends signals to the skin that prompt the lowest layer of cells to rise to the surface so quickly that they lack the maturity to protect the underlying layers of skin cells. Red patches covered with silvery scales result. Often, psoriatic patches itch. The scalp, elbows, knees and back are targets of psoriasis. The nails can develop pits that look like they're the result of a very slender ice pick.

The choice of medicine rests on where the patches are, how severe the outbreak is and the type of psoriasis a person has. Topical medicines are chosen to treat moderate to mild outbreaks. "Topical" indicates that the medicine is applied directly to the skin. Dovonex (a synthetic version of vitamin D) and Vectical ointment are two widely used topicals.

Stronger medicines belong to the cortisone family. Temovate and Diprolene are two examples.

Methotrexate and cyclosporine are two oral medicines that correct the immune system's excesses.

The newest psoriasis treatments are biological agents designed to rein in the wayward immune system. Their names include Enbrel, Remicade, Humira, Amevive and Stelara. They're administered in the doctor's office.

This information isn't of much use to you. All the above medicines require a prescription. Your best bet for conquering psoriasis is putting yourself in the care of a dermatologist, who can choose for you the medicines that will give you the best chance of controlling this often distressing skin illness.

Link:
Large menu of treatments for psoriasis